RT Journal Article SR Electronic T1 Serious infections with antirheumatic therapy: are biologicals worse? JF Annals of the Rheumatic Diseases JO Ann Rheum Dis FD BMJ Publishing Group Ltd and European League Against Rheumatism SP iii54 OP iii57 DO 10.1136/ard.2006.058503 VO 65 IS suppl 3 A1 Winthrop, K L YR 2006 UL http://ard.bmj.com/content/65/suppl_3/iii54.abstract AB This paper reviews the current evidence for the role of antirheumatic therapy in the development of serious infections in patients with rheumatoid arthritis (RA). Prednisone is clearly associated with increased infectious risk, but no definitive data link methotrexate to infection. Emerging data suggest that biological agents also pose increase infectious risk, particularly when used in combination with corticosteroids or methotrexate. Further research is needed in this important aspect of RA treatment. In the meantime, the author recommends that physicians should remain vigilant for serious infections in their patients with RA and use appropriate vaccines and screening procedures to mitigate their risk.